A prospective, real-world, interventional study to evaluate the effect of mepolizumab on achieving clinical remission in participants with severe asthma. - 219871

Glaxosmithkline Research & Development Limited0 个研究点目标入组 336 人开始时间: 2024年1月24日最近更新: 2024年8月21日

适应症

试验速览

暂无简介。

•1. Adults aged 18 years or over 2. Participant has a confirmed asthma diagnosis and has been prescribed NUCALA by their physician for the treatment of asthma, as per local label. 3. No NUCALA use in the 6 months prior to enrollment (unless as stated in inclusion criteria 2) 4. Participants with =60% predicted FEV1 (Forced expiratory volume in 1 second) and =4 exacerbations per year, as confirmed by the physician 5. Other local prescription criteria of NUCALA not described above at NUCALA initiation (e.g., local reimbursement criteria) 6. Written informed consent

•1. Investigator concerns about participant’s willingness to adhere to biologic treatment for any reason (e.g., cost, behavior, difficulty with access to healthcare) 2. Participants currently on maintenance oral corticosteroids (mOCS) or intramuscular corticosteroids 3. Participants using omalizumab, reslizumab, dupilumab, tezepelumab, or benralizumab within the 6 months prior to enrollment 4. Participating in an interventional study with a treatment intervention 5. Other clinically significant respiratory conditions (e.g., bronchiectasis, pulmonary fibrosis) 6. Current smokers

发起方